Last reviewed · How we verify
continuous infusion of 5-fluorouracil
continuous infusion of 5-fluorouracil is a pyrimidine analog Small molecule drug developed by Japan Clinical Oncology Group. It is currently in Phase 3 development for Adjuvant treatment of colon cancer, Treatment of advanced colorectal cancer.
5-fluorouracil is a thymidylate synthase inhibitor that disrupts DNA synthesis and function.
5-fluorouracil is a thymidylate synthase inhibitor that disrupts DNA synthesis and function. Used for Adjuvant treatment of colon cancer, Treatment of advanced colorectal cancer.
At a glance
| Generic name | continuous infusion of 5-fluorouracil |
|---|---|
| Sponsor | Japan Clinical Oncology Group |
| Drug class | pyrimidine analog |
| Target | thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
5-fluorouracil works by inhibiting thymidylate synthase, an enzyme necessary for DNA synthesis. This leads to the disruption of DNA replication and function, ultimately causing cell death in rapidly dividing cancer cells.
Approved indications
- Adjuvant treatment of colon cancer
- Treatment of advanced colorectal cancer
Common side effects
- Mucositis
- Diarrhea
- Leukopenia
- Stomatitis
- Nausea
Key clinical trials
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus (PHASE2)
- A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC) (PHASE2)
- A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer (PHASE2)
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (PHASE1, PHASE2)
- Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma (PHASE1, PHASE2)
- Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) (PHASE1, PHASE2)
- Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- continuous infusion of 5-fluorouracil CI brief — competitive landscape report
- continuous infusion of 5-fluorouracil updates RSS · CI watch RSS
- Japan Clinical Oncology Group portfolio CI
Frequently asked questions about continuous infusion of 5-fluorouracil
What is continuous infusion of 5-fluorouracil?
How does continuous infusion of 5-fluorouracil work?
What is continuous infusion of 5-fluorouracil used for?
Who makes continuous infusion of 5-fluorouracil?
What drug class is continuous infusion of 5-fluorouracil in?
What development phase is continuous infusion of 5-fluorouracil in?
What are the side effects of continuous infusion of 5-fluorouracil?
What does continuous infusion of 5-fluorouracil target?
Related
- Drug class: All pyrimidine analog drugs
- Target: All drugs targeting thymidylate synthase
- Manufacturer: Japan Clinical Oncology Group — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Adjuvant treatment of colon cancer
- Indication: Drugs for Treatment of advanced colorectal cancer
- Compare: continuous infusion of 5-fluorouracil vs similar drugs
- Pricing: continuous infusion of 5-fluorouracil cost, discount & access